Bacterial Vaginosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Bacterial Vaginosis - Pipeline Review, H2 2016

Bacterial Vaginosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Bacterial Vaginosis - Pipeline Review, H2 2016
Published Jul 13, 2016
61 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Bacterial Vaginosis - Pipeline Review, H2 2016, provides an overview of the Bacterial Vaginosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
- The report reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects
- The report assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and

  
Source:
Document ID
GMDHC8231IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Bacterial Vaginosis Overview71
Therapeutics Development82
  Pipeline Products for Bacterial Vaginosis Overview81
  Pipeline Products for Bacterial Vaginosis Comparative Analysis91
Bacterial Vaginosis Therapeutics under Development by Companies101
Bacterial Vaginosis Therapeutics under Investigation by Universities/Institutes111
Bacterial Vaginosis Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Bacterial Vaginosis Products under Development by Companies151
Bacterial Vaginosis Products under Investigation by Universities/Institutes161
Bacterial Vaginosis Companies Involved in Therapeutics Development176
  Alfa Wassermann S.p.A171
  AmVac AG (Inactive)181
  Evofem, Inc.191
  Osel, Inc.201
  Starpharma Holdings Limited211
  Symbiomix Therapeutics, LLC221
Bacterial Vaginosis Therapeutics Assessment237
  Assessment by Monotherapy Products231
  Assessment by Target241
  Assessment by Mechanism of Action251
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Drug Profiles3018
  Amphora Drug Profile302
  AMV-100 Drug Profile321
  astodrimer Drug Profile334
  benzoyl peroxide Drug Profile371
  LACTIN-V Drug Profile381
  rifaximin Drug Profile394
  secnidazole Drug Profile432
  Small Molecule for Bacterial Vaginosis and Candidiasis Drug Profile451
  subtilosin Drug Profile461
  TOL-463 Drug Profile471
Bacterial Vaginosis Dormant Projects481
Bacterial Vaginosis Discontinued Products491
Bacterial Vaginosis Product Development Milestones5010
  Featured News &Press Releases501
    May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing501
    May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis501
    Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis511
    Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora521
    Oct 14, 2015: Additional US Patent granted for VivaGel BV521
    Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV531
    Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food531
    Aug 27, 2015: Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation541
    Aug 06, 2015: Symbiomix Therapeutics' First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG551
    Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis561
    May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis561
    Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated571
    Nov 21, 2014: SYM-1219 Chosen as one of the Top Infectious Disease Projects to Watch by Therapeutic Area Partnerships581
    Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis581
    Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial591
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bacterial Vaginosis - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bacterial-Vaginosis-Pipeline-Review-H2-2016-2088-16164>
  
APA:
Global Markets Direct - Market Research. (2016). Bacterial Vaginosis - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bacterial-Vaginosis-Pipeline-Review-H2-2016-2088-16164>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.